STAAR Surgical Reports Mixed Fiscal 2025 Results Amid China Market Recovery
Event summary
- STAAR Surgical reported $57.8M in Q4 2025 net sales, up 18.1% YoY, but fiscal year 2025 net sales declined 23.7% YoY to $239.4M.
- Gross margin improved to 75.7% in Q4 2025 from 64.7% a year ago, but net loss narrowed to $(18.3)M from $(34.2)M.
- China market demand improved with mid-single-digit recovery, but inventory reductions led to lower-than-anticipated Q4 sales.
- Company repurchased 376,000 shares under a $30M program, with $23.5M remaining.
- Interim co-CEOs Warren Foust and Deborah Andrews appointed; search for permanent CEO underway.
The big picture
STAAR Surgical's fiscal 2025 results reflect a mixed performance, with improvements in gross margin and cost management offset by declines in net sales due to China market dynamics. The company's focus on inventory rebalancing and the launch of the EVO+ ICL in China positions it for potential growth, but the leadership transition and market uncertainties remain key watchpoints. The broader industry trend of increasing myopia prevalence underscores the strategic importance of STAAR's lens-based refractive surgery solutions.
What we're watching
- China Market Dynamics
- Whether STAAR can sustain growth in China amid rising average selling prices and market share gains.
- Profitability Path
- The pace at which STAAR achieves sustained profitability following cost reductions and inventory rebalancing.
- Leadership Transition
- How the search for a permanent CEO will impact strategic execution and long-term value creation.
Related topics